Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

The cautionary tale of PSA testing.

Hoffman RM, Zeliadt SB.

Arch Intern Med. 2010 Jul 26;170(14):1262-3. doi: 10.1001/archinternmed.2010.222. No abstract available.

PMID:
20660847
2.

Screening for prostate cancer - will we ever know?

Adolfsson J.

Acta Oncol. 2010 Apr;49(3):275-7. doi: 10.3109/02841861003696803. No abstract available.

PMID:
20397764
3.

Is an improved PSA screening test in sight?

Savage L.

J Natl Cancer Inst. 2007 Oct 17;99(20):1503-4. Epub 2007 Oct 9. No abstract available.

4.

PSA screening isn’t “nonsense”—it saved my life.

Orwig S.

J Fam Pract. 2011 Aug;60(8):453. No abstract available.

PMID:
21928548
5.
6.

[PSA-based early detection of prostate cancer].

Luboldt H, Rübben H.

Urologe A. 2000 Jan;39(1):22-6. Review. German.

PMID:
10663192
7.

PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.

Perrin P.

Eur Urol. 2006 Mar;49(3):418-9. Epub 2006 Jan 4. No abstract available.

PMID:
16459016
8.

[Biological markers of prostate cancer].

Seitz C, Djavan B.

Ann Urol (Paris). 2006 Dec;40(6):329-35. Review. French.

PMID:
17214230
9.

The science and art of prostate cancer screening.

Yao SL, Lu-Yao GL.

J Natl Cancer Inst. 2011 Mar 16;103(6):450-1. doi: 10.1093/jnci/djr047. Epub 2011 Feb 24. No abstract available.

10.

Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

Belpomme D, Irigaray P.

J Natl Cancer Inst. 2010 Apr 7;102(7):506-7. doi: 10.1093/jnci/djq045. Epub 2010 Feb 26. No abstract available.

11.

Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence.

Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM.

J Natl Cancer Inst. 2007 Oct 17;99(20):1510-5. Epub 2007 Oct 9.

12.

The prostate cancer pseudo-epidemic.

Adami HO.

Acta Oncol. 2010 Apr;49(3):298-304. doi: 10.3109/02841860903584945.

PMID:
20397765
13.

PSA screening: the bottom line.

Elhilali MM.

CMAJ. 2000 Mar 21;162(6):791-2. No abstract available.

14.

Efficacy vs effectiveness in prostate-specific antigen screening.

Albertsen PC.

J Natl Cancer Inst. 2010 Mar 3;102(5):288-9. doi: 10.1093/jnci/djq002. Epub 2010 Feb 8. No abstract available.

15.

Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?

Barry MJ, Mulley AJ Jr.

J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10. No abstract available.

16.

PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.

Shimbo M, Tomioka S, Sasaki M, Shima T, Suzuki N, Murakami S, Nakatsu H, Shimazaki J.

Jpn J Clin Oncol. 2009 Nov;39(11):727-31. doi: 10.1093/jjco/hyp091. Epub 2009 Aug 12.

17.
18.

Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?

Carroll PR, Whitson JM, Cooperberg MR.

J Clin Oncol. 2011 Feb 1;29(4):345-7. doi: 10.1200/JCO.2010.32.5308. Epub 2010 Dec 28. No abstract available.

19.

[The significance of early detection for prostate cancer in mass screening].

Kato M, Tammbo M, Yoshimatsu T, Ohta M, Kinjyo M, Noda H, Watanabe K, Miyata A, Murata A, Miura I, Yoneda T, Yoshii M, Okegawa T, Kojima M, Sayama T, Nutahara K, Higashihara E.

Nihon Hinyokika Gakkai Zasshi. 2001 Jan;92(1):23-9. Japanese.

20.

[From antigen to tumor marker. Results of research regarding PSA and its clinical applications].

De Angelis G, Brandt B, Schmid HP, Semjonow A.

Urologe A. 2000 Jul;39(4):309-12. Review. German.

PMID:
10957771
Items per page

Supplemental Content

Write to the Help Desk